Piramal Pharma Limited
Canara Robeco Mutual Fund, which last reported a 1.0 percent stake in Piramal Pharma Limited, is no longer on the list of disclosed shareholders, indicating either a complete sale or a reduction to below the 1 percent reporting threshold.
A pharmaceutical company operating across three major segments: contract development and manufacturing organisations, complex hospital generics for critical care, and consumer healthcare products. Established through the acquisition of Nicholas Laboratories in 1988, the company has expanded via strategic mergers and acquisitions alongside organic growth initiatives. It serves healthcare providers and consumers across India through its diversified business operations and specialized pharmaceutical solutions.
Joint venture between Canara Bank and Robeco of Netherlands. Manages over Rs 1.5 lakh crore. Canara Robeco Equity Hybrid Fund and Canara Robeco Emerging Equities are among its best-regarded offerings with long consistent track records. Backed by the Canara Bank network for distribution across Tier 2 and Tier 3 India.